Search results
Heart Disease in Pregnancy: Maternal and Neonatal Risk
Author(s):
Rofila Dita Karmia
,
Mefri Yanni
,
Yusrawati
,
et al
Added:
2 months ago
Original Research
Author(s):
Karol Mirkowski
,
Ercole Vellone
,
Bernadetta Żółkowska
,
et al
Added:
1 year ago
Author(s):
Gregg Stone
Added:
1 year ago
THT Conference 2025 - Outcomes after heart failure patients were treated with an interatrial shunt show heart failure with reduced ejection fraction (HFrEF) patients had further benefit compared to heart failure with preserved ejection fraction (HFpEF) patients. The study's prediction model revealed four independent predictors of two-year adverse outcomes in HFrEF patients treated with medical…
View more
Author(s):
Thomas Modine
Added:
9 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Author(s):
Jelena Celutkiene
,
Alexandre Mebazaa
,
Jan Biegus
,
et al
Added:
1 year ago
Author(s):
Barry Borlaug
Added:
5 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT…
View more
Undiagnosed Sleep Apnoea Linked to Adverse Myocardial Remodelling in Hypertrophic Cardiomyopathy
Added:
5 months ago
Source:
Radcliffe Cardiology
News
Author(s):
Vlado Perkovic
Added:
1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Author(s):
Deepak L Bhatt
Added:
11 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants…
View more
Author(s):
Javed Butler
,
Shelley Zieroth
,
Gianluigi Savarese
Added:
1 year ago
Radcliffe Medical Education, is proud to bring to you this roundtable series which is designed to equip healthcare professionals with the knowledge and tools necessary to identify high-risk patients indicative of worsening HF and to implement effective management strategies. Watch Dr Javed Butler (Baylor Scott & White Health, Dallas, US); Dr Shelley Zieroth (University of Manitoba, Winnipeg, CA)…
View more
